{"transactions":[{"id":2526805,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":2874595,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302588},"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526804,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":2874595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302588},"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526803,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":9486166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":998544},"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526802,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":9486166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":998544},"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526801,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":1613632,"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526800,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering."}],"balance_after":1613632,"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526799,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":302588,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":1301132,"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526798,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":302588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."}],"balance_after":1301132,"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526797,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":998544,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":998544,"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2526796,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T16:20:18.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":998544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."}],"balance_after":998544,"source":{"system":"sec-edgar","filing":"0000899243-21-042710","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321042710/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-28"}},{"id":2532936,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":2874595,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302588},"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532935,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":2874595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":302588},"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532934,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":9486166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":998544},"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532933,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":9486166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":998544},"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532932,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":302588,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":1301132,"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532931,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":302588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."}],"balance_after":1301132,"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532930,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":998544,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom."}],"balance_after":998544,"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}},{"id":2532929,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":133951,"kind":"organization","name":"SV7 Impact Medicine Fund LP","position":1,"cik":"0001780602","reported_name":"SV7 Impact Medicine Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":133952,"kind":"organization","name":"SV7 (IMF) GP LLP","position":2,"cik":"0001889859","reported_name":"SV7 (IMF) GP LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-28T12:55:17.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":998544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021."}],"balance_after":998544,"source":{"system":"sec-edgar","filing":"0000899243-21-041838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1889859/000089924321041838/doc4.xml","form_type":"4"}}]}